Status: Not yet recruiting
Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)
The usual first treatment for Pneumocystis jirovecii pneumonia (PCP) is an antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX). However, some patients cannot take this medication because of allergies, side effects, or lack of response. This study asks the question: When TMP-SMX cannot be used, which alternative treatment for PCP provides the best balance of effectiveness and safety?
Participants needed: 416
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: McGill University Health Centre/Research Institute of the McGill University Health CentreUpdated: Jan 21, 2026
Eligibility criteria
Immunocompromised patients (including but not limited to HIV, solid organ transp... [+5]
The Platform will exclude: patients where we are unable to obtain informed conse... [+13]